Licensing status

Publication and contact information

Drug platforms

Elafin-secreting lactic acid bacteria for treating inflammatory bowel disease (IBD)

Elafin-secreting lactic acid bacteria could be useful for treating IBD. Two food-grade strains of lactic acid bacteria were engineered to express the protease inhibitor elafin, which is downregulated in the colons of patients with IBD. In a mouse model of chemically induced colitis, oral delivery of the engineered bacterial strain restored intestinal homeostasis and decreased gut inflammation compared with wild-type bacteria. Next steps include evaluating the safety of the engineered bacteria.
ViThera Pharmaceuticals Inc. is developing the engineered bacteria for use in IBD (see IBD's bacteria cafeteria, page 8).

SciBX 5(44); doi:10.1038/scibx.2012.1174
Published online Nov. 8, 2012

Patented; licensed to ViThera Pharmaceuticals

Motta, J.-P. et al. Sci. Transl. Med.;
published online Oct. 31, 2012;
Contact: Nathalie Vergnolle,
Institut National de

la Santé et de la Recherche Médicale (INSERM), Toulouse, France